Drug · CHEMBL535

SUNITINIB

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. SUNITINIB. Drugs and targets, record CHEMBL535. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL535

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: SUNITINIB; ChEMBL
ChEMBL ID: CHEMBL535; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Sunitinib accord; ChEMBL
Other names: NSC-736511, NSC-750690, SU-011248, SU-11248, SU011248; ChEMBL
Other form: SUNITINIB MALATE, CHEMBL1567; Drugs and targets
DrugBank: DB01268; DrugBank
InChIKey: WINHZLLDWRZWRT-ATVHPVEESA-N; ChEMBL
Open Targets' highest stage: Approval, for 4 of its 102 diseases, from ATC, ClinicalTrials.gov, EMA Human Drugs and TTD; Open Targets

Targets14

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
CSF1R	Macrophage colony-stimulating factor 1 receptor	Macrophage colony stimulating factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/1436
FLT1	Vascular endothelial growth factor receptor	Vascular endothelial growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/2321
FLT1	Vascular endothelial growth factor receptor 1	Vascular endothelial growth factor receptor 1 inhibitor	INHIBITOR	https://conductscience.org/library/genes/2321
FLT3	Receptor-type tyrosine-protein kinase FLT3	Tyrosine-protein kinase receptor FLT3 inhibitor	INHIBITOR	https://conductscience.org/library/genes/2322
FLT4	Vascular endothelial growth factor receptor	Vascular endothelial growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/2324
FLT4	Vascular endothelial growth factor receptor 3	Vascular endothelial growth factor receptor 3 inhibitor	INHIBITOR	https://conductscience.org/library/genes/2324
KDR	Vascular endothelial growth factor receptor	Vascular endothelial growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/3791
KDR	Vascular endothelial growth factor receptor 2	Vascular endothelial growth factor receptor 2 inhibitor	INHIBITOR	https://conductscience.org/library/genes/3791
KIT	Mast/stem cell growth factor receptor Kit	Stem cell growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/3815
PDGFRA	Platelet-derived growth factor receptor alpha	Platelet-derived growth factor receptor alpha inhibitor	INHIBITOR	https://conductscience.org/library/genes/5156

1 to 10 of 14Source ChEMBL

See all 14 targets

Diseases102

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
renal cell carcinoma	Approval	ClinicalTrials.gov and EMA Human Drugs	101	99	https://conductscience.org/library/drugs?q=MONDO_0005086
gastrointestinal stromal tumor	Approval	ClinicalTrials.gov, EMA Human Drugs and TTD	26	23	https://conductscience.org/library/drugs?q=MONDO_0011719
breast cancer	Phase 3	ClinicalTrials.gov	23	23	https://conductscience.org/library/drugs?q=MONDO_0007254
non-small cell lung carcinoma	Phase 3	ClinicalTrials.gov	14	14	https://conductscience.org/library/drugs?q=MONDO_0005233
colorectal cancer	Phase 3	ClinicalTrials.gov	11	11	https://conductscience.org/library/drugs?q=MONDO_0005575
clear cell renal carcinoma	Phase 2	ClinicalTrials.gov	10	10	https://conductscience.org/library/drugs?q=MONDO_0005005
prostate cancer	Phase 3	ClinicalTrials.gov	9	9	https://conductscience.org/library/drugs?q=MONDO_0008315
glioblastoma	Phase 2/3	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0018177
pancreatic neuroendocrine tumor	Phase 2	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=MONDO_0019954
kidney cancer	Phase 3	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0002367

1 to 10 of 102Source Open Targets

See all 102 diseases

Trials324

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00326898	Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery	Phase 3	1,943	2016-12-12	sunitinib	Its name	ClinicalTrials.gov
NCT00720941	Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma	Phase 3	1,110	2013-06-17	sunitinib	Its name	ClinicalTrials.gov
NCT02231749	Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)	Phase 3	1,096	2018-10-16	sunitinib	Its name	ClinicalTrials.gov
NCT00699374	Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer	Phase 3	1,075	2013-01-14	sunitinib	Its name	ClinicalTrials.gov
NCT02811861	Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma	Phase 3	1,069	2021-09-24	sunitinib	Its name	ClinicalTrials.gov
NCT00457392	A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone	Phase 3	960	2011-08-02	sunitinib	Its name	ClinicalTrials.gov
NCT00676650	Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy	Phase 3	873	2013-03-08	sunitinib	Its name	ClinicalTrials.gov
NCT00457691	Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer	Phase 3	768	2011-06-03	sunitinib	Its name	ClinicalTrials.gov
NCT00083889	SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma	Phase 3	750	2009-12-10	SU011248	Its name	ClinicalTrials.gov
NCT01306045	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies	Phase 2	647	2023-04-11	sunitinib	Its name	ClinicalTrials.gov

1 to 10 of 324

See all 324 trials

Comparisons in its trials87

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Nivolumab + Ipilimumab vs Sunitinib: deaths from any cause	159 of 547	202 of 535	1,082	NCT02231749	Trial comparisons
Nivolumab + Ipilimumab vs Sunitinib: serious adverse events	305 of 547	213 of 535	1,082	NCT02231749	Trial comparisons
Sunitinib vs Sorafenib: serious adverse events	240 of 526	204 of 542	1,068	NCT00699374	Trial comparisons
Sunitinib + Erlotinib vs Erlotinib: serious adverse events	207 of 473	181 of 477	950	NCT00457392	Trial comparisons
Sunitinib and Prednisone vs Placebo and Prednisone: serious adverse events	275 of 581	86 of 285	866	NCT00676650	Trial comparisons
FOLFIRI + Sunitinib vs FOLFIRI + Placebo: Number of Participants With Overall Confirmed Objective Response	124 of 386	128 of 382	768	NCT00457691	Trial comparisons
FOLFIRI + Sunitinib vs FOLFIRI + Placebo: serious adverse events	170 of 384	111 of 379	763	NCT00457691	Trial comparisons
SU011248 vs IFN-α: Objective Response, Core Radiology Assessment	145 of 375	29 of 375	750	NCT00083889	Trial comparisons
SU011248 vs IFN-α: Objective Response, Investigator's Assessment	171 of 375	45 of 375	750	NCT00083889	Trial comparisons
Participants With mRCC and/or aRCC: First Line Sunitinib Treatment vs Participants With mRCC and/or aRCC: Second Line Axitinib Treatment: Number of Participants Who Started Systemic Therapy Within 1 Year of Diagnosis	367 of 622	63 of 121	743	NCT04033991	Trial comparisons

1 to 10 of 87

See all 87 comparisons in its trials

Papers from its trials271

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41801644	RESULT	1	PubMed
41277563	RESULT	1	PubMed
36302173	RESULT	1	PubMed
30865533	RESULT	1	PubMed
28448384	RESULT	1	PubMed
28301826	RESULT	1	PubMed
26671977	RESULT	1	PubMed
26416414	RESULT	1	PubMed
26264378	RESULT	1	PubMed
25991462	RESULT	1	PubMed

1 to 10 of 271

See all 271 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL535

GET https://conductscience.org/api/drugs/v1/CHEMBL535/diseases?page=2

API reference For AI assistants